The antidepressant venlafaxine ameliorates murine experimental autoimmune encephalomyelitis by suppression of pro-inflammatory cytokines.
D000818:Animals; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D002999:Clone Cells; D003511:Cyclohexanols / Q000627:therapeutic use*; D016207:Cytokines / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D005911:Gliosis / Q000473:pathology; D007150:Immunohistochemistry; D007155:Immunologic Factors; D008070:Lipopolysaccharides / Q000494:pharmacology; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D012313:RNA / Q000096:biosynthesis / Q000302:isolation & purification; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013601:T-Lymphocytes / Q000276:immunology; D000069470:Venlafaxine Hydrochloride
D018687:Antidepressive Agents, Second-Generation; D003511:Cyclohexanols; D016207:Cytokines; D007155:Immunologic Factors; D008070:Lipopolysaccharides; D012313:RNA; D000069470:Venlafaxine Hydrochloride